Ensign Peak Advisors
KALV

Ensign Peak Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Ensign Peak Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-47,116
Closed -$1.13M – 1865
2021
Q2 		$1.13M Hold
47,116
– – ﹤0.01% 1400
2021
Q1 		$1.21M Buy
47,116
+29,386
+166% +$772K ﹤0.01% 1351
2020
Q4 		$337K Buy
+17,730
New +$304K ﹤0.01% 1661
2020
Q3 		– Sell
-4,253
Closed -$51K – 1757
2020
Q2 		$51K Hold
4,253
– – ﹤0.01% 1660
2020
Q1 		$33K Sell
4,253
-4,253
-50% -$57.4K ﹤0.01% 1612
2019
Q4 		$151K Buy
+8,506
New +$111K ﹤0.01% 1631

Other funds holding KALV

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ensign Peak Advisors's KALV Position: Q3 2021 in Review

Ensign Peak Advisors sold out of KalVista Pharmaceuticals (KALV) in Q3 2021, closing a stake of 47,116 shares — an estimated $1.13M sold.

Ensign Peak Advisors first reported a position in KALV in Q4 2019 and held it in 6 quarters. The position peaked at $1.21M in Q1 2021. 105 funds tracked by Wall St. Rank hold KALV as of Q3 2021.

  • Ensign Peak Advisors reported no remaining KalVista Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ensign Peak Advisors sold 47,116 KalVista Pharmaceuticals shares in Q3 2021, an estimated $1.13M.
  • Ensign Peak Advisors first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 6 quarters.
  • Ensign Peak Advisors's KalVista Pharmaceuticals position peaked at $1.21M in Q1 2021.
  • 105 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2021.

Based on Ensign Peak Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.